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Abstract
Lipid nanoparticles (liposomes) were first described in 1965, and several work have led to development of
important technical advances like triggered release liposomes and drug-loaded liposomes. These advances have led
to numerous clinical trials in such diverse areas such as the delivery of anti-cancer, antifungal, and antibiotic drugs;
the delivery of gene medicines; and most importantly the delivery of anesthesia drugs. Quite a number of
liposomes are on the market, and many more are still in developmental stage. Lipid nanoparticles are the first
nano-medicine delivery system to be advanced from laboratory concept to clinical application with high
considerable clinical acceptance. Drug delivery systems for local anesthetics (LAs) have caught the interest of many
researchers because there are many biomedical advantages connected to their application. There have been several
formulation techniques to systemically deliver LA that include encapsulation in liposomes and complexation in
cyclodextrins, nanoparticles, and to a little extent gold nanoparticles. The proposed formulations help to decrease
the LA concentration utilized, increase its permeability, and most importantly increase the localization of the LA for
a long period of time thereby leading to increase in the duration of the LA effect and finally to reduce any local
and systemic toxicity. In this review, we will highlight on new updates pertaining to drug delivery of local
anesthetics in particular bupivacaine using lipid nanoparticles.
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Introduction
A drug delivery system should have reduced tissue reac-
tion, an efficient drug release capability, and a steady
degradation rate for biodegradable carrier until all non-
harmful products are passed out [1, 2]. For local anes-
thetics (LAs), the formulations of new potent delivery
systems is aimed at modulating and controlling the re-
lease rate of these drugs, improve their anesthetic effect,
and enhance their localization thereby reducing side ef-
fects associated with systemic toxicity [3]. LAs are im-
portant clinically for anesthesia and analgesia for
management of acute and chronic pain after surgery and
also reducing systemic toxicity and blocking sensory fi-
bers though they may only last for few hours [4, 5].
For an excellent drug delivery system for LA to be de-
signed/formulated, previous research studies have outlined
two important factors that must be considered: (1) the
drug has to be adequately transported in order to sustain
a therapeutic concentration for a maximum period of time
and (2) carrier/drug excretion must be minimally reduced
for a decreased systemic concentration of the drug and its
concentration on the site of injection [6]. It should also be
noted that drug delivery systems for LA should act as a
store house at the injection site in which the carried LA
are slowly and gently released from these store house
thereby reducing risk of increased plasma levels, increased
period of nerve block, and decreased risk of systemic tox-
icity which is of great importance to patients with surgical
or chronic pain [7, 8].
Recently, the application of local anesthetic drugs to
provide postsurgical analgesia has been welcomed by
great scientific and clinical interest [9]. However, local
anesthetic drugs have short action period, so neural
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blockade enhancers like dexamethasone are often ad-
ministered in combination with these anesthetic drugs.
There are varieties of local anesthetics available includ-
ing lidocaine, bupivacaine, and ropivacaine being some
of the most commonly used [10]. Bupivacaine and ropi-
vacaine have demonstrated to produce longer peripheral
neural blockade (4.5–12 h) than lidocaine (1–2 h) as
such bupivacaine is commonly used for long-acting
anesthetic effects; however, it is also linked with compel-
ling cardiotoxicity and neurotoxicity [11]. The toxicity of
bupivacaine has been overcome by ropivacaine, the pro-
pyl analog of bupivacaine while still maintaining the
same duration of action [12]. Additionally, ropivacaine
shows a lower lipid solubility and vasodilation when
compared with bupivacaine resulting in their increased
circulation time within the delivered local environment
[13]. While promising, local anesthetics need a continu-
ous admixture to maintain and sustain an efficient post-
surgical pain management, or else it can result to
complex side effects like adverse local tissue reactions
and systemic toxicity [14]. The application of biomate-
rials to develop a controlled release technique for local
anesthetics has been efficient to deliver a non-lethal, lo-
calized, and postsurgical pain management system [15].
Over the years, researchers have formulated quite a
number of biomaterial-based carriers, including lipo-
somes microparticles and nanoparticles. These materials
have been proven to be efficient in the release of encap-
sulated drugs and in addition can diffuse freely from the
injection site [16].
Types of Local Anesthetics
Local anesthetics (LAs) are used mostly for anesthesia
and analgesia after surgery or for pain management,
which normally last for a few hours. To prolong the dur-
ation of local anesthesia, the use of catheter techniques,
disposable pumps, or multiple injections can be adopted
[D]. Prolonged LA action has only resulted in doubled
or tripled plain drug effect time, together with the use of
adjuncts with LA agents of readily available agents.
Local anesthetics can be categorized into two groups
based on the nature of the chemical link, namely amides
[−NH–CO–] and esters [−O–CO–] (Figs. 1 and 2). The
amide group is more clinically important; it includes lig-
nocaine, prilocaine, levobupivacaine, bupivacaine, mepi-
vacaine, and ropivacaine.
The ester group of LA includes cocaine, procaine,
chloroprocaine, and amethocaine, and they have been
reported to be weak bases and solubilized for injection
as strong conjugate acidic hydrochloride salts at a of pH
3–6 by (Fig. 3) [17, 18].
For topical and mucous formulations, benzocaine and
butamben are the most commonly used ester type of
local anesthetics. Dewachter reported the clinical advan-
tage of amide group over ester group in that anaphylaxis
to local anesthetics is very rare and has reduced the fre-
quency of acute allergic reaction because of the decreas-
ing use of the ester group of local anesthetics [19]. In
addition, the metabolic product of the ester local
anesthetic like para-aminobenzoic acid is mostly respon-
sible for allergic reactions [19]. Cross-reactivity among
esters is common.
However, there are allergic reactions associated with
amide local anesthetics but remain anecdotal. It should
be noted that ingredients like antioxidants or preserva-
tives included in local anesthetic may also produce aller-
gic or adverse reactions [19].
Mechanisms of Action of Local Anesthetics
Local anesthetics directly block transmission of pain
sensation from nociceptive afferent nerves. Local
anesthetic agents are injected directly, and their po-
tency results from action on the nerve where the in-
ward sodium ion (Na+) current is blocked at the
sodium ionophore during depolarization process [20].
LAs are also responsible for blocking calcium ions
(Ca2+) and potassium ions (K+) channels and potential
vanilloid-1 receptors [21]. Local anesthetics also alter
the linking bond between some certain G proteins
and their associated chemical receptors; so through
this ability, LAs are able to carry out their anti-
inflammatory effects, especially on neutrophil priming
reactions [22].
Lipid Nanoparticle/LA Drug Interaction
When a lipid nanoparticle loaded with an anesthesia
drug interacts with a cell, the delivery of the local
anesthesia drug and its distribution in the target cell can
be achieved in several ways: lipid nanoparticle loaded
with an anesthesia drug interacts with the cell, binding
to the surface via the receptors (1). Absorption onto the
plasma membrane can also occur by electrostatic inter-
actions (2). The delivery of the cargo into the cell cyto-
plasm can take place through different ways. Lipid
nanoparticles fuse with the plasma membrane of the cell
and empty the anesthesia drugs into the cell (3). After
the interaction with the cell, the structure of the lipid
Fig. 1 Basic structure of local anesthetics
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nanoparticle bilayer can be affected and the anesthesia
drug is released (4). Exchange of carrier-lipid compo-
nents with the cell membrane can also occur (5). Lipid
nanoparticles engulfed by endocytosis (6) can either fol-
low these paths: endosomes fuse with lysosomes (7): in
this case, the anesthesia drug is released as a result of
breakdown of the liposome membrane by low PH. Endo-
somes follow another route (8): lipid nanoparticle re-
leases their loaded drug after the degradation of the
endocytic vesicle (Fig. 4) [23].
Toxicity of Local Anesthetics
Systemic toxicity is caused by increased concentrations
of local anesthetics. They happen when there is an acci-
dental discharge of anesthesia drugs into the systemic
circulation. The central nervous system is the most
prone and sensitive to the toxic action of local anesthetic
agents and cardiovascular system and can result into
symptoms like isolated muscle contractures, incoherent
speech, generalized convulsions, unconsciousness, etc.
[24]. Recently, Cai and his colleagues demonstrated in
their study that bupivacaine, tetracaine, and etidocaine
increases tendency and possibilities to impair the proper
functioning of both the cardiovascular system and cen-
tral nervous system compared with lidocaine, mepiva-
caine, and prilocaine [25]. The central nervous system is
more sensitive and prone to the toxic effects of local an-
esthetics than the cardiac system because it depends
upon sodium channels for proper functioning, and it is
the first to typically manifest signs of toxicity above the
normal pharmacological dose of the administered LA
drug (Table 1).
Toxic Effects on Central Nervous System
The initial CNS symptoms are tinnitus, blurred vision,
dizziness, tongue parathesias, and circumoral numbness.
Excitatory signs such as nervousness, agitation, restless-
ness, and muscle twitching are the result of blockade of
inhibitory pathways. While the early signs advance to
Fig. 2 Amide local anesthetics
Fig. 3 Amide local anesthetic (lignocaine) and ester local anesthetic (procaine)
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CNS depression with slurred speech, drowsiness, uncon-
sciousness, and then respiratory arrest.
Toxic Effects on Cardiovascular System
Local anesthetics have directed toxic effects on the heart
and peripheral blood vessels. They block the fast sodium
channels in the fast-conducting tissue of Purkinje fibers
and ventricles leading to a reduced rate of depolarization
as well as the effective refractory period and action po-
tential duration (https://www.openanesthesia.org/loca-
l_anesthetics_systemic_toxicity/).
Liposomal Bupivacaine and Its Functional Platform for
Anesthesia Drug Delivery
Recently, liposomal bupivacaine has been applied in clin-
ical practice and has been investigated in many clinical
trial studies on healthy patient volunteers in order to
procure a long-lasting pain relief in a single dose admin-
istration (DepoFoam bupivacaine, Exparel™) (Table 2).
Liposomal bupivacaine is made up of liposomal spheres
with a radius size of 15.6 μm± 17.8 [26].
Recent in vitro studies comparing the Exparel™ com-
plex with bupivacaine hydrochloride 0.5 % (w/v) and
1.31 %, respectively, regarding controlled release system,
with the same amount of active substance have been car-
ried out, and it was reported that the release kinetics
profile was different in the case of hydrochloride from
free bupivacaine with a peak time release of 48 h, while
concerning Exparel™ complex and the peak time release
was about 800 h [27] (Table 3).
In Bramlett et al.’s study, bupivacaine-loaded lipid
nanoparticle was demonstrated to provide benefit in
total knee arthroplasty (TKA); in that study of 138 TKA,
Bramlett compared several doses of DepoFoam (lipid
nanoparticle bupivacaine) against bupivacaine hydro-
chloric acid (HCl) in wound infiltration [28]; it was re-
ported that the highest dose of bupivacaine-loaded lipid
nanoparticle of 532 mg was the only effective dose that
was capable of producing improved pain scores in the
TKA patients at rest over the bupivacaine, and was
found to be dose-related [29] (Fig. 5) (Table 4).
Fig. 4 Lipid nanoparticle-cell interaction
Table 1 Showing the pharmacological data for the two LA
groups
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Lipid nanoparticles have several characteristics such
as biodegradable, decreased toxic, and solubilized
drug delivery system that have been widely utilized in
biomedical field, also lipid nanoparticle formulations
have demonstrated several abilities to improve on the
pharmacokinetics and pharmacodynamics of the
loaded encapsulated drugs; in addition, it have been
showed to be a potent drug carrier for several drugs
like insulin, sildenafil citrate, amphotericin B, and
methotrexate [30] (Fig. 6). Presently, there are few or
no research studies that have investigated the encap-
sulation of LA into lipids nanoparticles [31]. However,
there are few available clinical studies that have inves-
tigated and compared the differences between EMLA
(lidocaine 2.5 % and prilocaine 2.5 %) and liposomal
systems for several local anesthesia agents (Table 4).
Recently, lipid nanoparticle bupivacaine has been in-
vestigated to provide up to 72 h of analgesia effect
after hemorrhoidectomy surgery, thereby decreasing
administration of opioids.
One of such research studies results reported by
Bucalo and his colleagues stated that liposomal lidocaine
preparations is more efficient than non-lipid nanoparti-
cle vehicles in terms of increased time duration of
Table 2 Summary of liposomal bupivacaine application
Author Study design Result
McAlvin et al. [51] To evaluate the effect of liposomal bupivacaine on the
sciatic nerve in experimental models
Histological evaluation reported that both Exparel complex
and bupivacaine hydrochloride produce tissue reaction
with the liposomal complex being less aggressive.
Lonner et al. [52] To study the role of liposomal bupivacaine in pain
management after total joint arthroplasty and observed
that liposomal bupivacaine pharmacokinetics and
pharmacodynamics
Liposomal bupivacaine has less cardiac toxic effects, less
cardiac toxic effects, without significant differences
between Exparel™ and placebo: palpations and
extrasystoles (≤2 %), tachycardia (3.9 %), bradycardia
(1.6 %), hypertension and hypotension (≤2 %).
Richard et al. [53] To study any hematological, biochemical, and biological
side effects of Exparel complex in laboratory animals
(1) Histological analysis reported that there was evidence
of granulomatous inflammation, 15 days after
administration of Exparel™ formulation.
(2) There was maintenance of optimum plasma
concentration for about 96 h.
(3) Administration of liposomal bupivacaine to
postoperative patients reduces the intake of opioids, the
hospital admission period, and costs of bills.
Soberón et al. [49] Study was carried out on a 45-year-old woman with
digital ischemia on the ring finger and little finger at the
right hand.
(1) It was reported that the results were superior to the
subclavicular block due to a better and efficient pain
control.
(2) It was reported that after surgery, photo-
plethysmography, showed a normal ulnar artery and loss
of finger cyanosis, as a result of vasodilation effect pro-
duced by liposomal bupivacaine.
Table 3 Examples of marketed liposomal for anesthesia drug and other drugs
Trade name Nanoparticle platform Drug Size Indication
Anti-cancer
Doxil/Caelyx (Janssen) PEG-liposomes Doxorubicin 100 nm Kaposi’s sarcoma, ovarian cancer, breast cancer,
combination with bortezomib in multiple myeloma
DaunoXome (Galen) Lipid nanoparticle Daunorubicin 45–80 nm Kaposi’s sarcoma
DepoCyt (Pacira) Lipid nanoparticle Cytarabine 20 μm Malignant lymphomatous meningitis
Marqibo (Talon) Lipid nanoparticle Vincristine 100 nm Acute lymphoblastic leukemia
Myocet (Cephalon) Lipid nanoparticle Doxorubicin 80–90 nm Combination therapy with cyclophosphamide in
breast cancer
Analgesics
Diprivan (Fresenius Kabi) Lipid emulsion Propofol 180 nm Anesthesia
DepoDur (Pacira) Lipid nanoparticle Morphine 17–23 μm Postsurgical pain
Exparel (Pacira) Lipid nanoparticle Bupivacaine 24–31 μm Anesthesia
Antifungal
Abelcet (Sigma-Tau) Lipid drug particles Amphotericin B 2–5 μm Aspergillosis
AmBisome (Astellas) Liposome Amphotericin B <100 nm Antifungal, leishmaniasis
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anesthesia [32]. Furthermore, other studies have also in-
vestigated clinical comparisons between EMLA (lido-
caine 2.5 % and prilocaine 2.5 %) and 5 % lipid
nanoparticle tetracaine for skin anesthesia. Taddio and
his research teammates demonstrated the effect of local
anesthesia of a new lipid nanoparticle formulation made
up of 4 % lidocaine in a randomized controlled trial, and
it was reported that the lipid nanoparticles formulation
exhibited a brief action duration of about 30 min, being
potent for cutaneous analgesia in children [33]. Another
research study on the use of lipid nanoparticle to encap-
sulate anesthesia drugs reported that after the injection
Fig. 5 Plasma bupivacaine concentration after administration of DepoFoam bupivacaine or bupivacaine HCl to patients undergoing total
knee arthroplasty
Table 4 Summary of studies assessing the efficacy of bupivacaine-loaded lipid nanoparticle






300 mg compared with
0.9 % sodium chloride
Numerical rating score
(NRS), AUC 0–72 h
Pain intensity scores were
significantly decreased in the
extended release bupivacaine
group versus placebo (141.8 vs.






600 mg compared with
bupivacaine HCL 200 mg þ
epinephrine 1:200,0000
NRS-Activity, AUC 0–72 h No statistical difference between
the groups (AUC NRS-A, 441 vs.





Bunionectomy DepoFoam 120 mg
compared to 0.9 % sodium
chloride
NRS AUC 0–24 h Pain intensity score was
significantly decreased in lipid
nanoparticle bupivacaine versus
control, 123.9 in DepoFoam









(133, 266, 399, and 532 mg)
compared to bupivacaine
HCl 150 mg with
epinephrine 1:200,000
NRS-A, AUC 0–96 h No statically significant
difference between all
DepoFoam groups versus
bupivacaine HCl (P > 0.05).
Cohen et al.
[56]
Cohort study Colectomy DepoFoam 366 mg
compared with
postoperative PCA
Total milligrams of opioids
consumed after surgery
and total cost of
hospitalization
Mean total amount of
postsurgical opioids significantly
less in DepoFoam compared to
PCA group (57 vs. 115 mg, P 1⁄4
0.025). Average cost of
hospitalization significantly less in
DepoFoam versus PCA (US$ 8766
vs. US$ 11,850 P 1⁄4 0.027).
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of lipid nanoparticle bupivacaine, increased plasma con-
centrations were sustained for longer time period with
the liposomal bupivacaine when compared with plain
bupivacaine [34].
In another recent clinical study, a large multi-vesicular
bupivacaine formulation was investigated in six healthy
volunteers through intradermal injections in various in-
jection sites like the lower back, with different percent-
ages of 0.5, 1.0, and 2 % of lipid nanoparticle
bupivacaine; 0.5 % plain bupivacaine; 0.9 % saline; and
sham liposomes. The calculated median time duration of
analgesia effect with 0.5 % bupivacaine was 1 h; with 0.5,
1.0, and 2.0 % liposomal bupivacaine; this was increased
to 19, 38, and 48 h, respectively [35].
The introduction of lipid nanoparticle bupivacaine has
paved a way for several randomized trials investigating
the potency and safety of this new delivery system
(Table 3). Gorfine et al. carried out a multicenter, ran-
domized, double-blind, parallel-group placebo-
controlled phase 3 research study to compare the po-
tency and time duration of postsurgical analgesia effect
from a single dose of lipid nanoparticle bupivacaine with
placebo administered intra-operatively in patients under-
going hemorrhoidectomy. In this study, all the patients
were randomly assigned to receive DepoFoam bupiva-
caine placebo made up of 30 ml of 0.9 % sodium chlor-
ide and 10 mg of morphine was administered
intramuscularly as postsurgical pain control for every 4
to 6 h as necessary for the first 3 days of the postsurgical
period [36, 37]. The primary end point and secondary
outcome of this study are summarized in Table 4. Con-
clusively, it was reported that the administration of lipid
nanoparticle bupivacaine resulted in a statistically sig-
nificant pain reduction within 3 days, reduced opioid in-
take compared with placebo after hemorrhoidectomy
[38].
In another randomized, multicenter, double-blinded
study conducted by Smoot et al., to investigate the
extent and time duration of analgesia effect achieved
with lipid nanoparticle loaded bupivacaine in patients
undergoing cosmetic and sub-muscular augmentation
mammoplasty under general anesthesia, 136 patients
were randomized to either a single dose of lipid nano-
particles bupivacaine 600 mg or bupivacaine HCl (0.5 %
bupivacaine with epinephrine 1:200,000). Then, 1000 mg
of acetaminophen was administered to all patients three
times a day and rescue oxycodone as mandatory 3 days
after surgery [39]. The primary end point and secondary
outcome of this study are summarized in Table 4. Fi-
nally, this study reported that the cumulative amounts
of opioid taken were significantly lower in the lipid
nanoparticle bupivacaine group through 24 h and
through 48 h as such the authors concluded that lipid
nanoparticle bupivacaine is promising as regards effi-
ciency compared with bupivacaine HCl and required less
opioid intake [40].
Furthermore, another randomized, double-blind phase
3 clinical study on bunionectomy patients, and a total of
193 patients were randomized to receive either lipid
nanoparticle bupivacaine 120 mg or placebo through
wound infiltration. All the patients were sedated by ad-
ministering propofol with Mayo block with up to 25 ml
of 2 % lidocaine with epinephrine. The patients received
either 180 mg (8 ml) of DepoFoam bupivacaine or the
placebo, and 8 ml of 0.9 % sodium chloride, 30 min after
the Mayo block was administered. The primary end
point and secondary outcome of this study are summa-
rized in(Table 4. Conclusively, the study showed that
lipid nanoparticle bupivacaine provided improved pain
relief and reduced intake of opioid after bunionectomy,
compared with placebo [4].
Cohen et al. carried out an open-label cohort study to
investigate the total opioid burden and health economic
outcomes in adult patients undergoing open segmental
colectomy [41] with anastomosis with general anesthesia
who were administered with received lipid nanoparticle
Fig. 6 Lipid nanoparticle (a) and a loaded lipid nanoparticle with local anesthesia drug (b)
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bupivacaine for postsurgical pain compared with those
who were administered with patient-controlled analgesia
(PCA) with opioids. The primary end point and second-
ary outcome of this study are summarized in Table 4.
The results showed that the lipid nanoparticle bupiva-
caine group had significantly reduced total postsurgical
opioid use than the PCA group [42].
A new product, EXPAREL™ (Pacira Pharmaceuticals
Inc., NJ, USA), made up of DepoFoam (MLV) liposomal
bupivacaine has been developed and according to a new
clinical study, patients that were administered Depo-
Foam bupivacaine had decreased rescue analgesia ur-
gency compared with plain 0.5 % bupivacaine at 24 h
[43]. However, the calculated mean cumulative pain
scores at rest or without rest were the same, as were res-
cue medication necessities at all other time points up to
3 days but it should be noted that muscular pain was re-
ported in 6 out of 66 (9 %) patients administered with
DepoFoam bupivacaine, but none was reported with
plain bupivacaine [44].
Recent research works have demonstrated the effi-
cacy of nanoparticle in a rat model where local anal-
gesia was reported administered to nine of ten
animals treated with bupivacaine-loaded nanofibers,
with the effect of the LA been observed at day 1 and
maximum effect observed at day 3; however, the ob-
served effect was lost between 7 and 9 days. In
addition, Chen and other researchers developed a
sandwich-structure electrospun fiber mat that is made
up of two outer layers and an inner layer consisting
of PLGA/collagen fibers and PLGA fibers respectively
containing two antibiotics drugs and one anesthetic
drug, namely gentamycin and vancomycin and lido-
caine, respectively leading to promising repair of in-
fected wounds in a rat model carried out in vivo.
Weldon and his colleagues also developed an electro-
spun nanofiber that provided a promising sustained
local analgesia using bupivacaine [45].
Furthermore, and recently, there has been a develop-
ment of local anesthetics skin-delivery systems using
lipid nanoparticles, and this technique has been chan-
neled into commercial formulations such as lidocaine
and prilocaine cream, leading to modified release rate of
drugs, increased bio-adhesive abilities, and reduced tox-
icity, thereby improving therapeutic potency [46].
Previous research works have developed a safe and
sustained analgesia effect for 48 h after administration of
local anesthetic injection of 2 % lipid nanoparticle ligno-
caine [47]. In addition, it was reported that after an epi-
dural injection of lipid nanoparticle bupivacaine, there
was a twofold increase in the time duration of the anal-
gesia effects [48]. Furthermore, research studies in the
field of intraoral topical anesthesia reported that lipid
nanoparticle-encapsulated 2 % ropivacaine gel was as
potent as 20 % benzocaine gel in decreasing pain incurred
during needle injection and activating soft-tissue
anesthesia [49]. Recently, in a randomized single-blinded,
placebo-controlled research study, lipid nanoparticle-
encapsulated ropivacaine formulations (1 %, 2 %) was not
effective in decreasing the pain of needle injection into the
palatal mucosa. In another blinded cross-over study, two
anesthesia drug effects were compared and evaluated in
intraocular patients [17]. The injection discomfort was
compared between 2 and 3 % lipid nanoparticle-
encapsulated mepivacaine with 2 % mepivacaine with
1:100,000 adrenalines and 3 % mepivacaine. The encapsu-
lation of mepivacaine was responsible for the increase in
the time duration of anesthesia drug effects and decreased
the discomfort or side effects caused by these
vasoconstrictor-associated formulations [50].
Conclusions
The development of local anesthetic drugs has become
an alternative to decrease pain and anxiety linked to in-
vasive surgeries. Anesthesia drug like DepoFoam bupiva-
caine is a promising and efficient new method to deliver
bupivacaine and may serve as a potent instrument in
postoperative pain control. A good comparison between
plain bupivacaine and lipid nanoparticle bupivacaine has
demonstrated to showcase many advantages when used
in wound infiltration that includes opioid-sparing effect,
prolonged analgesia, higher patient satisfaction, prompt
discharge, and reduced hospital bills.
Presently, different strategies and techniques have
been purposed for local anesthetic drug delivery that in-
clude mostly lipid nanoparticles and formulations of
hydrogels leading to a fast and specific delivery and pro-
longation of the duration of anesthesia; however, with
the promising future of lipid nanoparticles application in
bio-medical fields, more multicenter clinical trials are
needed to be carried out.
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